While the benefit of treatment has been mainly investigated in the setting of metastatic, castrate-resistant prostate cancers, PSMA-targeted radiopharmaceuticals may also be beneficial in a hormone-sensitive, metastatic prostate cancer setting, and with oligometastatic disease. The gene discussed is FOLH1; the disease is prostate carcinoma.